Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Advanced Drainage Systems Inc — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B), while Advanced Drainage Systems Inc trades at $125.56 (market cap $9.52B). The key difference: Advanced Drainage Systems Inc is far larger — about 4.2× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SLS | WMS | |
|---|---|---|
Market Cap | $2.27B | $9.52B |
Volume | 4,179,659 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $15.46 | $175.38 |
52-Week Low | $1.39 | $125.33 |
Enterprise Value | $2.14B | $11.12B |
Typical Hold Time | — | 43 Days |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Advanced Drainage Systems (WMS) trades at $126.08, down 3.07% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.49 exceeding expectations. Revenue for 2025 was $2.90 billion, with a net income margin of 15.5%. The company maintains strong profitability metrics, including a 24.9% ROE, and recently announced a quarterly dividend. Analyst consensus is mixed with a $188.70 price target, while institutional activity shows both new acquisitions and reductions in holdings.
WMS presents a balanced outlook with solid fundamentals and recent earnings beats offset by near-term technical weakness. Investment opportunities include sustained revenue growth and margin expansion from operational efficiencies. Key risks involve competitive pressures in the construction sector and potential volatility from macroeconomic factors. The stock's current valuation at a P/E of 21.48 offers a reasonable entry point relative to growth prospects, but investors should monitor cash flow trends given the projected net cash outflow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
